SCHEMBL29537520

SCHEMBL29537520

C=C1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 11/20 1.00
KDM4E B2RXH2 10/20 1.00
RECQL P46063 8/20 1.00
HPGD P15428 8/20 1.00
HSD17B10 Q99714 7/20 1.00
USP2 O75604 7/20 1.00
THRB P10828 6/20 1.00
NR1I2 O75469 2/20 1.00
LMNA P02545 2/20 1.00
MC4R P32245 1/20 1.00
SIRT5 Q9NXA8 1/20 1.00
MEN1 O00255 7/20 0.98
KMT2A Q03164 7/20 0.98
MAPT P10636 6/20 0.98
L3MBTL1 Q9Y468 6/20 0.98
POLB P06746 3/20 0.98
RAD52 P43351 1/20 0.98
ALDH1A1 P00352 5/20 0.67
HIF1A Q16665 3/20 0.67
TSHR P16473 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26597994 1.00 TDP1 (1.00) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL30567156 1.00 TDP1 (1.00) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL26628251 1.00 TDP1 (1.00) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL19555132 1.00 TDP1 (1.00) TDP1KDM4ERECQLHPGDHSD17B10
Hydrochloric Acid SCHEMBL29413670 0.99 TDP1 (1.00) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL23247761 0.86 TDP1 (0.78) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL29487299 0.86 TDP1 (0.78) TDP1KDM4ERECQLHPGDHSD17B10
SCHEMBL4015 0.85 TDP1 (0.73) TDP1KDM4ERECQLHPGDHSD17B10
Hydrochloric Acid SCHEMBL20398184 0.83 TDP1 (0.71) TDP1KDM4ERECQLHPGDHSD17B10
Methacycline SCHEMBL19771282 0.82 TDP1 (0.70) TDP1KDM4ERECQLHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022094079-A1 METHODS OF TREATING CYSTIC FIBROSIS THE TRUSTEES OF DARTMOUTH COLLEGE (US) 2022-05-05 WO claimed
US-20230338340-A1 Methods of Treating Cystic Fibrosis DARTMOUTH COLLEGE (US) 2023-10-26 US disclosed
EP-4045055-A1 COMBINATION OF ZIDOVUDINE WITH A TETRACYCLINE ANTIBIOTIC Helperby Therapeutics Limited (GB) 2022-08-24 EP disclosed
CN-114765956-A Combinations of zidovudine and tetracycline antibiotics 赫尔普百治疗有限公司 2022-07-19 CN disclosed
US-11371020-B2 Uses of epithelial-to-mesenchymal inhibitors in generating pacemaker cells EMORY UNIVERSITY (US) 2022-06-28 US disclosed
WO-2022094079-A1 METHODS OF TREATING CYSTIC FIBROSIS THE TRUSTEES OF DARTMOUTH COLLEGE (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338340-A1 Methods of Treating Cystic Fibrosis CFTR, DAB2IP, CTTN TDP1 3740/4885KDM4E 4381/4885RECQL 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.